A research study published by a number of scientists in Italy demonstrates that green tea extracts do have a positive impact in treating malaria, in vitro, which confirms Plandai's study results.
|
Read more...
|
Lost in the dog days of August is the remarkable performance of Nuvilex, Inc. (OTCQB – NVLX) relative to the market and some of its key peers. Over the past ten days, while biotech stocks have largely come under pressure, Nuvilex has not only held its own but remains well above its key daily moving averages (DMA).
|
Read more...
|
Nuvilex is moving yet another step closer toward introducing a game-changing multi-disease treatment platform that is potentially worth billions in annual sales.
|
Read more...
|
In our view, one of the major overhangs on the shares of LIG Assets, Inc. (OTCPK – LIGA - $0.0065 – Spec Buy) has been related to the presentation of the Company’s financials. Yesterday’s news coming out of LIG’s Dallas HQ has got to provide investors with a high degree of comfort in the corporate financials, going forward.
|
Read more...
|
Once or perhaps twice a year, something happens to a stock that smacks it down on strong volume. These events are usually triggered by misunderstandings or disinformation
|
Read more...
|
A potential takeover target, GRILLiT is a growing Latin-Caribbean fusion restaurant chain that marries fast casual with nutritious and healthy food and is riding the fast casual dining wave.
|
Read more...
|
As we near the end of the dog days of August, the relatively sleepy and under-followed Plandaí¬ Biotechnology, Inc. (OTCQB – PLPL - $0.61 - Spec Buy) has matched its 52-week high this week and appears primed to move substantially higher.
|
Read more...
|
Given the substantial costs to administer and conduct clinical trials exclusively in the U.S., it is likely that Nuvilex, Inc. (OTCQB – NVLX- $0.165 – Spec Buy) will elect to turn to overseas locations for future clinical trials.
|
Read more...
|
With a flurry of news on the research and development front in recent weeks, it appears as if investors have forgotten about the market opportunity in Europe that lies ahead for Plandaí¬ Biotechnology (OTC QB – PLPL - $0.54 – Spec Buy).
|
Read more...
|
In addition to its success wildly successful digital publishing business, LifeApps Digital Media, Inc. (OTCQB – LFAP - $0.07 – Spec Buy) is having a solid 2H13 selling promotional and personalized team athletic apparel products via its subsidiary the Sports One Group.
|
Read more...
|
|
|
<< Start < Prev 31 32 33 34 35 36 37 38 39 40 Next > End >>
|
Page 33 of 47 |